on september 4, the 13th china innovation and entrepreneurship competition (chongqing division) and the the 10th chongqing "high-tech cup" mass innovation competition concluded successfully in the high-tech zone. chongqing zhijian life technology company, a company incubated by jinfeng laboratory, won the first prize in the growth enterprise group of the china innovation and entrepreneurship competition (chongqing division) with its "ai + pathology" innovation project and will represent the chongqing division in the national finals of the china innovation and entrepreneurship competition.

since its establishment more than two years ago, jinfeng laboratory has been guided by national strategic needs and with "next-generation diagnosis of major diseases" as its core mission, attracting domestic and foreign research teams to explore organized scientific research and carry out research around the "pathological phenotype science plan" basic original research, building a cross-scale multi-modal disease imaging technology system, striving to realize new systems and new methods of disease classification, striving to create a source of innovation for the precision diagnosis industry, and making golden contributions to the cultivation and development of new productive forces. the laboratory is committed to building a collaborative innovation ecosystem of "medical industry, academia and research funding" and accelerating the transformation of scientific and technological achievements through matrix services such as government policy support, clinical collaboration with medical institutions, industrial resource docking, talent support in universities and colleges, and innovation fund investment.

so far, the laboratory has introduced a total of 16 technology companies in the field of life and health to settle in the high-tech zone.